|
Home - Sunitix
Sunitix is an oncology product. It is used to treat cancer by preventing the activity of a special group of proteins which are known to be involved in the gr...
|
82 % |
|
Ibrutinib-home
Ibrutix: Ibrutix is the Global First Generic Ibrutinib. An orally bioavailable, small-molecule inhibitor of Bruton's tyrosine kinase (BTK) with potential ant...
|
80 % |
|
High LDL-C Injection Treatment | Repatha® (evolocumab) HCP
Learn how Repatha® can reduce the risk of major adverse cardiovascular (CV) events and lower high LDL-C in adult patients at increased risk of these events....
|
78 % |
|
SinABiomedics | Revolutionizing CLL Treatment with Cutting-Edge Biotechnology
|
76 % |
|
BioFicher | Global Pharmaceutical Product Development
BioFicher Sciences is a premier global healthcare cloud-based technology and clinical research organization, offering expertise in pharmaceutical product dev...
|
76 % |
|
Home | epiSCI: Epithelial Stem Cell Innovation for Lead Optimization
The right in vitro platform to develop the right drug, delivered to the right cells, in the right patient. Clinical Trial on a Dish (TM)
|
75 % |
|
WELIREG® (belzutifan) | Official Patient Website
Learn more about WELIREG® (belzutifan), one oral medicine approved to treat two different conditions. Learn about another treatment option here.
|
75 % |
|
ARENSIA · Expert for Exploratory Clinical Trials in Patients
ARENSIA Exploratory Medicine is a privately owned company specialized in the performance of early clinical trials and early clinical research in patients.
|
74 % |
|
Bard Cancer Diagnostics – Non-invasive Cancer Imaging | 212-355-7017
|
74 % |
|
Preclinical & Clinical Research Services | Pharmahungary
Leading European CRO offering preclinical and clinical research services, cardiovascular R&D, large animal models, bioinformatics tools, and innovative drug...
|
73 % |
|
Welcome to BESPONSA® | BESPONSA®
|
73 % |
|
Cirugia Colon y Recto | Tratamiento de Hemorroides en San Luis Potosi
|
73 % |
|
SMALL MOLECULE INHIBITORS OF STAT3 PROTECT AGAINST ANGIOTENSIN II
|
73 % |
|
MESI-STRAT – Systems Medicine of Metabolic-Signaling networks – A New Conept for Breast Cancer Patient Stratification
|
73 % |
|
Pediatrics & Gastro Institute
Pediatrics & Gastro Institute
|
73 % |
|
Constant Therapeutics
Constant Therapeutics LLC is a private biopharmaceutical company developing peptide and small molecule drugs. clinical stage company developing Mas receptor...
|
73 % |
|
HYPERICUM LifeScience GmbH | Biotech | Vienna, Austria
Hypericum LifeScience GmbH: an innovativ Biotech Company located in Vienna, specializing in the field of Photodynamic Tumour Therapy; Drug Development, Biote...
|
73 % |
|
For healthcare professionals | NERLYNX® (neratinib) tablets
NERLYNX® (neratinib) tablets is indicated for the treatment of early-stage HER2+ breast cancer following adjuvant trastuzumab-based therapy and metastatic HE...
|
73 % |
|
GenHarp Clinical Solutions – Improving Medical Conditions for Future Generations
|
73 % |
|
Home - pwh-dev.co.uk
|
73 % |
Detected social media networks